Kamada Secures FDA Approval for San Antonio Plasma Center with 50,000L Capacity and $8M–$10M Annual Revenue
Kamada's new San Antonio plasma center is FDA-cleared to collect 50,000 liters of normal and specialty plasma annually. At full capacity, the 11,100-square-foot facility with 50 donor beds is projected to contribute $8 million to $10 million in yearly revenue.
1. FDA Approval and Inspection
The FDA completed its February inspection of Kamada’s 11,100-square-foot San Antonio facility and granted clearance to commence commercial normal source plasma sales. This marks Kamada’s third FDA-approved plasma center in Texas, complementing existing operations in Houston and Beaumont.
2. Facility Capacity and Revenue Potential
The center features 50 donor beds and is designed to collect approximately 50,000 liters of plasma annually. At full capacity, sales of normal source plasma are expected to generate between $8 million and $10 million in yearly revenue.
3. Specialty Plasma Collection Focus
Beyond standard plasma, the San Antonio site is equipped to collect specialty plasma products such as anti-rabies and anti-D. Its scale positions it among the largest U.S. centers for specialty plasma collection, supporting Kamada’s hyper-immune therapy production.
4. Next Regulatory and Growth Strategy
Following U.S. clearance, Kamada plans to seek European Medicines Agency approval for the site to expand its international collection network. The new center aligns with the company’s strategy to drive profitable growth through ramped-up plasma operations, proprietary product commercialization and strategic partnerships.